Question

A 59-year-old with type 2 diabetes (A1C 7.6%) and CKD (eGFR 38 mL/min/1.73 m², UACR 250 mg/g) is on ACE inhibitor. Best next pharmacologic addition to reduce CKD progression and CV events?

Accepted Answer

SGLT2 inhibitor

Answer

Sulfonylurea

Answer

GLP-1 receptor agonist only

Answer

Thiazolidinedione

Answer

DPP-4 inhibitor

Practice question

A 59-year-old with type 2 diabetes (A1C 7.6%) and CKD (eGFR 38 mL/min/1.73 m², UACR 250 mg/g) is on ACE inhibitor. Best next pharmacologic addition to reduce CKD progression and CV events?